|
Significant Accounting Policies - Additional Information (Detail)
|
3 Months Ended | 9 Months Ended | 9 Months Ended | 9 Months Ended | 3 Months Ended | 3 Months Ended | 9 Months Ended | 9 Months Ended | 3 Months Ended | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2014
USD ($)
|
Sep. 30, 2014
VEF
|
Sep. 30, 2014
USD ($)
|
Sep. 30, 2014
VEF
|
Sep. 30, 2013
USD ($)
|
Dec. 31, 2013
USD ($)
|
Dec. 31, 2012
USD ($)
|
Sep. 30, 2014
Venezuela [Member]
|
Sep. 30, 2013
Venezuela [Member]
|
Dec. 31, 2013
Venezuela [Member]
|
Feb. 28, 2013
SITME rate [Member]
|
Feb. 28, 2013
New CADIVI rate [Member]
|
Feb. 28, 2013
Previous CADIVI rate [Member]
|
Sep. 30, 2013
Remeasurement of assets and liabilities using new CADIVI rate [Member]
USD ($)
|
Dec. 31, 2013
SICAD [Member]
USD ($)
|
Dec. 31, 2013
SICAD [Member]
CADIVI rate [Member]
USD ($)
|
Dec. 31, 2013
SICAD [Member]
CADIVI rate [Member]
VEF
|
Sep. 30, 2014
SICAD [Member]
CADIVI rate [Member]
|
Mar. 31, 2014
SICAD II [Member]
USD ($)
|
Mar. 31, 2014
SICAD II [Member]
VEF
|
Sep. 30, 2014
SICAD II [Member]
USD ($)
|
Sep. 30, 2014
SICAD II [Member]
Venezuela [Member]
USD ($)
|
Sep. 30, 2014
SICAD II [Member]
Selling, general and administrative expenses [Member]
USD ($)
|
Sep. 30, 2014
SICAD I [Member]
USD ($)
|
Jun. 30, 2014
SICAD I [Member]
USD ($)
|
Mar. 31, 2014
SICAD I [Member]
USD ($)
|
Mar. 31, 2014
SICAD I [Member]
Selling, general and administrative expenses [Member]
USD ($)
|
|
| Subsidiary or Equity Method Investee [Line Items] | |||||||||||||||||||||||||||
| Foreign currency exchange rate, Bolivars per USD | 5.3 | 6.3 | 4.3 | 11.3 | 56.2 | 56.2 | 50.0 | 10.7 | |||||||||||||||||||
| Foreign currency transaction losses | $ (15,100,000) | $ (500,000) | $ (700,000) | $ 98,000,000 | $ 17,100,000 | $ 200,000 | $ (86,100,000) | ||||||||||||||||||||
| CADIVI rate for remeasurement | 6.3 | 6.3 | 6.3 | ||||||||||||||||||||||||
| Currency exchanged through alternative legal exchange mechanisms | 600,000 | 1,100,000 | 6,800,000 | 100,000 | 5,300,000 | ||||||||||||||||||||||
| Reduction in cash and cash equivalents | (234,743,000) | (18,725,000) | 102,500,000 | (96,000,000) | |||||||||||||||||||||||
| Inventory write-downs in cost of sales | 17,729,000 | 17,536,000 | 7,600,000 | ||||||||||||||||||||||||
| Long lived asset impairments | 7,000,000 | ||||||||||||||||||||||||||
| Net monetary Bolivar denominated assets and liabilities | 31,400,000 | ||||||||||||||||||||||||||
| Cash and cash equivalents | 678,134,000 | 678,134,000 | 892,548,000 | 972,974,000 | 333,534,000 | 32,400,000 | |||||||||||||||||||||
| Subsidiary's net sales to Company's consolidated net sales, percentage | 3.00% | 5.00% | |||||||||||||||||||||||||
| Subsidiary asset as percentage of consolidated assets | 2.00% | 10.00% | |||||||||||||||||||||||||
| Purchase price of bonds invested in Bolivar denominated bonds | 4,200,000 | 48,000,000 | 11,818,000 | 113,400,000 | |||||||||||||||||||||||
| Other-than-temporary impairments relating to available-for-sale securities | $ 9,800,000 | $ 13,000,000 | |||||||||||||||||||||||||